Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

1.

The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms.

Jiang CL, Liu L, Li Z, Buttgereit F.

Steroids. 2015 Jun 26. pii: S0039-128X(15)00192-0. doi: 10.1016/j.steroids.2015.06.015. [Epub ahead of print] Review.

PMID:
26122209
2.

Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.

Alten R, Holt R, Grahn A, Rice P, Kent J, Buttgereit F, Gibofsky A.

Scand J Rheumatol. 2015 Jun 26:1-5. [Epub ahead of print]

PMID:
26114379
3.

Effects of PVA coated nanoparticles on human immune cells.

Strehl C, Gaber T, Maurizi L, Hahne M, Rauch R, Hoff P, Häupl T, Hofmann-Amtenbrink M, Poole AR, Hofmann H, Buttgereit F.

Int J Nanomedicine. 2015 May 8;10:3429-45. doi: 10.2147/IJN.S75936. eCollection 2015.

4.

Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries.

Mattila K, Buttgereit F, Tuominen R.

Rheumatol Int. 2015 May 26. [Epub ahead of print]

PMID:
26007151
5.

Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis.

Santiago T, Jacobs JW, Saag KG, Buttgereit F, Pereira da Silva JA.

Acta Reumatol Port. 2015 Jan-Mar;40(1):10-22.

6.

What is the relationship between morning symptoms and measures of disease activity in patients with rheumatoid arthritis?

Boers M, Buttgereit F, Saag K, Alten R, Grahn A, Storey D, Rice P, Kirwan J.

Arthritis Care Res (Hoboken). 2015 Mar 25. doi: 10.1002/acr.22592. [Epub ahead of print]

PMID:
25807939
7.

Clocking in: chronobiology in rheumatoid arthritis.

Buttgereit F, Smolen JS, Coogan AN, Cajochen C.

Nat Rev Rheumatol. 2015 Jun;11(6):349-356. doi: 10.1038/nrrheum.2015.31. Epub 2015 Mar 24. Review.

PMID:
25800214
8.

Circadian rhythms in rheumatology--a glucocorticoid perspective.

Spies CM, Straub RH, Cutolo M, Buttgereit F.

Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S3. doi: 10.1186/ar4687.

9.

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.

Cutolo M, Spies CM, Buttgereit F, Paolino S, Pizzorni C.

Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S1. doi: 10.1186/ar4685.

10.

Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study.

Spies CM, Hoff P, Mazuch J, Gaber T, Maier B, Strehl C, Hahne M, Jakstadt M, Huscher D, Burmester GR, Detert J, Kramer A, Buttgereit F.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1):34-43. Epub 2014 Dec 22.

PMID:
25535886
11.

How to mechanistically explain the CONDOR study data.

Spies CM, Stemmler E, Buttgereit F.

Med Hypotheses. 2015 Jan;84(1):14-9. doi: 10.1016/j.mehy.2014.11.007. Epub 2014 Nov 15.

PMID:
25433956
12.

Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters.

Hoff P, Belavý DL, Huscher D, Lang A, Hahne M, Kuhlmey AK, Maschmeyer P, Armbrecht G, Fitzner R, Perschel FH, Gaber T, Burmester GR, Straub RH, Felsenberg D, Buttgereit F.

Cell Mol Immunol. 2015 Jul;12(4):483-92. doi: 10.1038/cmi.2014.106. Epub 2014 Nov 10.

PMID:
25382740
13.

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.

Detert J, Klaus P, Listing J, Höhne-Zimmer V, Braun T, Wassenberg S, Rau R, Buttgereit F, Burmester GR.

Trials. 2014 Oct 27;15:412. doi: 10.1186/1745-6215-15-412.

14.

Cellular energy metabolism in T-lymphocytes.

Gaber T, Strehl C, Sawitzki B, Hoff P, Buttgereit F.

Int Rev Immunol. 2015 Jan;34(1):34-49. doi: 10.3109/08830185.2014.956358. Epub 2014 Sep 26.

PMID:
25259409
15.

Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.

Zheng Y, Basel D, Chow SO, Fong-Yee C, Kim S, Buttgereit F, Dunstan CR, Zhou H, Seibel MJ.

Clin Exp Metastasis. 2014 Dec;31(8):921-33. doi: 10.1007/s10585-014-9680-3. Epub 2014 Sep 16.

PMID:
25223386
16.

Autoimmune rheumatic diseases.

Anaya JM, Shoenfeld Y, Buttgereit F, Gonzalez-Gay MA.

Biomed Res Int. 2014;2014:952159. doi: 10.1155/2014/952159. Epub 2014 Aug 5. No abstract available.

17.

Cytokine expression in human osteoblasts after antiseptic treatment: a comparative study between polyhexanide and chlorhexidine.

Röhner E, Hoff P, Gaber T, Lang A, Vörös P, Buttgereit F, Perka C, Windisch C, Matziolis G.

J Invest Surg. 2015 Feb;28(1):1-7. doi: 10.3109/08941939.2014.941445. Epub 2014 Aug 5.

PMID:
25093465
18.

Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis.

Mattila K, Buttgereit F, Tuominen R.

Rheumatol Int. 2014 Dec;34(12):1751-8. doi: 10.1007/s00296-014-3040-0. Epub 2014 May 29.

19.

Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.

Zheng Y, Chow SO, Boernert K, Basel D, Mikuscheva A, Kim S, Fong-Yee C, Trivedi T, Buttgereit F, Sutherland RL, Dunstan CR, Zhou H, Seibel MJ.

J Bone Miner Res. 2014 Sep;29(9):1938-49. doi: 10.1002/jbmr.2231.

PMID:
24676805
20.

Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity.

Strehl C, Buttgereit F.

Ann N Y Acad Sci. 2014 May;1318:1-6. doi: 10.1111/nyas.12364. Epub 2014 Feb 25.

PMID:
24611742
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk